UBS Global Healthcare Conference
Logotype for Biodesix Inc

Biodesix (BDSX) UBS Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Biodesix Inc

UBS Global Healthcare Conference summary

10 Nov, 2026

Nodify opportunity and Q3 performance

  • U.S. annual incidental lung nodule estimates are now 5M–6M; Nodify CDT flags likely malignancy, while XL2 identifies likely benign nodules.

  • Q3 diagnostic testing revenue was $23M, up 16% YoY; 19,400 tests were performed, up 24%, with FY revenue still expected to exceed $100M.

  • Q3 performance was affected by lower sales capacity and greater-than-expected primary-care seasonality; October brought the strongest new-physician acquisition month and improving existing-customer orders.

  • Primary care represents 15% of patient volume and about 50% of the market; its decisions focus on surveillance versus specialist referral, unlike pulmonologists’ procedure decisions.

  • Adding CDT for 4–8 mm nodules can lower average ASP because it is lower priced than XL2, while supporting earlier cancer detection and increased ordering of both tests; gross margin remained above 80% for six consecutive quarters.

Commercial execution and care pathways

  • Q3 average sales headcount was 101; plans were to reach ~110 and target ~115 by year-end, hiring 6–8 reps per quarter to match recruiting and training capacity.

  • Reps historically begin covering their costs within a quarter and typically reach stride in 6–9 months; some continue growing after several years in the field.

  • CHEST introduced a structured framework for nodule-management programs, identifying biomarkers as a key component; distribution to members and implementation work are underway, including two West Coast health systems.

  • Formal guideline updates were rumored for Q1–Q2 2027; broader use of automated patient identification, algorithmic ordering, blood-draw access and electronic integrations could reduce reliance on high-touch sales and lift orders per customer.

  • Health-system economics center on finding missed cancers and avoiding unnecessary interventions; health-economic evidence has supported pricing and Medicare rates, with alternative payer models under discussion.

Digital diagnostics and data strategy

  • A radiomics-based lung nodule assessment developed with Vanderbilt is targeted for commercialization in 2028 and is intended to complement blood-based Nodify tests with high-specificity imaging signals.

  • The STRATIFY study, announced at CHEST, will assess clinical utility of Nodify CDT and XL2 and validate a radiomic classifier alongside the blood test; study findings are expected to inform the optimal workflow and patient populations.

  • First digital-platform data were expected at RSNA within weeks, followed shortly thereafter by an initial publication with test performance data.

  • STRATIFY will combine blood samples and CT scans; the resulting multimodal dataset and Diagnostic Cortex machine-learning platform could support further lung diagnostics and potential biopharma collaborations.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Biodesix